fainting on semaglutide Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients, in support of patient access to authentic, FDA-approved medicines GLP-1s tied to elevated risk

In large-scale studies: 2,6,7 Average weight loss ranges from 2-6% of body weight (approximately 5-12 pounds for most people) About one-third of patients lose at least 5% of their body weight within a year Weight loss is sustained long-termstudies show benefits lasting up to 15 years with continued use Results improve with adherencethe longer people take it consistently, the better the outcomes Importantly, these positive changes occur even in people without type 2 diabetes

Patients should pay attention to their body's signals and adjust portion sizes as needed, as Ozempic often naturally reduces appetite

Individuals with a history of pancreatitis or those at a higher risk for pancreatitis should use GLP-1 analogues with caution

Louis found that GLP-1 medications were associated with lower risks of developing substance use disorders involving alcohol, nicotine, cannabis, cocaine, opioids, and other substances